



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/63, A61K 39/12, 39/295		A1	(11) International Publication Number: WO 99/63098 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number:	PCT/GB99/01387		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	5 May 1999 (05.05.99)		
(30) Priority Data:	9811433.3	29 May 1998 (29.05.98)	GB
(71) Applicant (for all designated States except US):	THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation and Research Agency, Ively Road, Farnborough, Hampshire GU14 0XL (GB).		
(72) Inventor; and			Published
(75) Inventor/Applicant (for US only):	BENNETT, Alice, Marie [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(74) Agent:	BOWDERY, A., O.; DERA, D/IPR, Formalities Section, Poplar 2, MOD Abbey Wood #19, Bristol BS34 8JH (GB).		

(54) Title: RECOMBINANT VENEZUELAN EQUINE ENCEPHALITIS VIRUS VACCINE

(57) Abstract

A prophylactic or therapeutic vaccine for use in protecting mammals such as humans or animals against Venezuelan Equine Encephalitis virus (VEE) is described. In particular, the vaccine comprises a recombinant virus such as a recombinant vaccinia virus which is able to express the structural genes of VEE in attenuated form, which has been modified to increase the protective effect of the vaccine. This is achieved by modifying the sequence of the attenuated VEE strain and/or putting this under the control of modified promoter which increases expression from the vector. Formulations of the vaccine as well as methods of treatment using the vaccine are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RECOMBINANT VENEZUELAN EQUINE ENCEPHALITIS VIRUS VACCINE

The present invention relates to a virus vaccine, specifically a vaccine to Venezuelan equine encephalomyelitis virus (VEE), to its preparation and pharmaceutically acceptable formulations and methods of prophylactic and therapeutic methods of treatment using said vaccine.

VEE virus is a mosquito-borne alphavirus which is an important cause of epidemic disease in humans and of epizootics in horses, donkeys and mules in certain parts of the world, in particular the South Americas.

The existing VEE vaccine, TC-83, was initially produced by attenuation of the Trinidad donkey strain (TRD) of VEE by sequential passage in guinea pig heart cell cultures. However, this vaccine is generally regarded as being inadequate for human vaccination. This is mainly due to the high incidence of side effects in vaccinees and the large proportion of vaccinees who fail to develop neutralising antibodies (Monath et al. 1992, Vaccine Research, 1, 55-68).

A vaccinia-based vaccine against VEE has been constructed (Kinney et al. J. Gen. Virol. 1988, 69, 3005-3013). In this recombinant, 26S RNA encoding structural genes of VEE were inserted into the NYCBH strain of vaccinia. The recombinant virus protected against sub-cutaneous challenge but had limited efficacy against aerosol challenge with VEE.

The virulent Trinidad donkey strain of VEE and the attenuated strain TC-83 have both been cloned and sequenced (R.M. Kinney et al. Virology (1989) 170, 19-30) and the amino acid and nucleotide numbering system used in this reference will be used hereinafter. This work has revealed that there are a number of amino acid changes between TRD and TC-83. The majority (five) of these changes occur within the gene encoding the glycoprotein E2.

The changes have been summarised as follows:

5	change	Table 1		Amino acid	
		Nucleotide	Position	TRD	TC-83
	22, junction region	A		G	non-coding
	1053, E ₂ -7	G		U	Lys Asn
	1285, E ₂ -85	C		U	His Tyr
	1391, E ₂ -120	C		U	Thr Arg
	1607, E ₂ -192	U		A	Val Asp
	1866, E ₂ -278	U		C	none
	1919, E ₂ -296	C		U	Thr Ile
	2947, E ₁ -161	U		A	Leu Ile
	3099, E ₁ -211	A		U	none
	3874, 3'-non-coding region	UU		U	non-coding

It has also been shown that the first 25 amino acids of the E2 glycoprotein represents a protective epitope. This region includes a single amino acid change (lys → asp) at amino acid 7 in the TC-83 construct as compared to the TRD strain. A 25bp synthetic peptide based on the TRD sequence VE2pep01(TRD), protected more mice from TRD virus challenge than a corresponding TC-83 based peptide (A.R. Hunt et al., Virology, 1990, 179, 701-711). More precise mapping of this epitope has been carried out (A.R. Hunt et al., Vaccine 1995, 13, 3, 281-288).

The applicants have found ways of increasing the protectiveness of a vaccine and in particular a vaccinia-based vaccine.

20 In particular, the applicants have found that the protectiveness of the vaccine may be increased either (a) by restoring the lysine residue at amino acid 7 of the E2 protein and/or (b) by modifying the promoter to increase expression of the protective construct.

25 Thus, in a first aspect, the present invention provides a vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine

comprising a vector which includes a sequence which encodes an attenuated form of said virus which is capable of producing a protective immune response, wherein the said sequence is such that the amino acid at position 7 in the E2 protein of VEE is 5 lysine.

Suitably, the attenuated form of the VEE virus comprises a derivative or variant of the TC-83 construct or an immunogenic fragment thereof.

10 Other attenuated forms may be produced by the skilled person, for example using known techniques such as serial passage through another organism, or by recombinant DNA technology, for instance by inactivating genes associated with the replication or virulence of the virus. The structural gene encoding the E2 15 glycoprotein or a fragment encoding at least the N-terminal 19 amino acids should be retained in order to retain immunogenicity of the construct.

Suitable fragments of the construct are those which include only 20 some of the structural genes of the VEE peptide or which encode only part of the proteins encoded by said genes, provided the construct encodes sufficient antigenic determinants to ensure that it is capable of producing a protective immune response in a mammal to whom the construct is administered.

25 As used herein, the term "variant" means that the construct is different to the original strain but that it encodes proteins and/or peptides which are the same or similar to those of wild-type VEE or immunogenic fragments thereof.

30 Thus, the changes in the nucleotide sequence may be silent in that they do not produce amino acid changes as compared to the original strain, or they may produce amino acid changes provided these do not alter function of the construct in terms of its ability to produce a protective immune response 35 against VEE. For example, the construct may encode peptides or proteins which are 60% homologous to the wild-type proteins or peptides, suitably more than 80% homologous and preferably more than 90% homologous to the native protein sequence, and provided they produce antibodies which are cross-reactive with 40 wild-type VEE, the protective effects of the construct may be retained.

"Derivatives" may have broadly similar structures but they are derived by manipulating the original constructs using recombinant DNA technology or chemical modification if appropriate.

5

The vector may contain the usual expression control functions such as promoters, enhancers and signal sequences, as well as a selection marker in order to allow detection of successful transformants. The selection of these will depend upon the 10 precise nature of the vector chosen and will be known to or readily determinable by a person skilled in the art.

Suitably the vector is a viral vector, for example a vector derived from *vaccinia*, *adenovirus*, or *herpes simplex virus* (HSV) 15 BCG or BCC. It is suitably attenuated itself, to minimise any harmful effects associated with the virus on the host.

Preferably, the vector is derived from *vaccinia* virus, as it has many properties which make it a suitable vector for vaccination, 20 including its ability to efficiently stimulate humoral as well as cell-mediated immune responses. *Vaccinia* has proven utility as a vaccine vehicle, following the Smallpox eradication programmes. It provides the potential for multi-valent vaccine construction and for oral administration. There are 25 many attenuated strains currently available.

A suitable selection marker for inclusion in a *vaccinia* vector is the *gpt* marker gene.

30 A VEE vaccine was constructed using a WR strain of *vaccinia* in this work. Preferably, a more highly attenuated strain of *vaccinia* which would be more acceptable for use in humans is employed. Such strains include Lister, which was used for wide scale vaccination against smallpox, NYVAC (Tartaglia et al, 35 (1992). *AIDS Research and Human Retroviruses* 8, 1445-1447) which contains specific genome deletions, or MVA (Mayr et al, (1975) *Infection* 3, 6-14) which is also highly attenuated.

40 Vaccines based upon viral vectors are suitably formulated for parenteral administration as described above. However, it is possible to formulate such vaccines for oral administration, for

example by incorporating the vector into a gut-colonising microorganism such as *Salmonella* and particularly *S. typhimurium*.

5 pTC-5A is a plasmid clone of cDNA encoding the structural genes of VEE virus strain TC-83 (Kinney et al. J. Gen. Virol. (1988) 69, 3005-30130). The VEE cDNA is situated downstream of the vaccinia 7.5K promoter which drives expression of the VEE structural proteins when the plasmid is used to construct recombinant vaccinia viruses.

10 Modified 7.5K vaccinia promoters have previously been prepared (Davison & Moss, J. Mol. Biol. 210, (1989) 749-769). It has been found that certain substitution mutations increase the strength of the promoter. By using synthetic promoters which include substitution mutations, the amount of VEE proteins produced from the recombinant

15 virus was increased.

Thus in a further aspect of the invention, there is provided a vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vaccinia virus vector which encodes an attenuated form of the VEE virus or a variant or fragment thereof which is capable of producing a protective immune response against VEE virus, expression of the said attenuated VEE virus being under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus protein production as compared to the wild-type 7.5K promoter.

In particular, it has been found that substitution mutations within the 7.5Kd promoter can be effective. These may be

30 illustrated by the following Table:

Wild-type 7.5K promoter:

TAAAAGTAGAAAAATATATTCTAATTTATTGCAC (SEQ ID No 1)

35

Substitution Mutations (emboldened)

TAAAAATTGAAAAT**A**CATTCTAATTTATTGCAC (SEQ ID No 2)

TAAAAT**T**GAAAAT**A**TATATTCTAATTTATTGCAC (SEQ ID No 3)

40

Inclusion of a synthetic 7.5K vaccinia promoter in WR103 has

been found to increase expression of the downstream VEE cDNA, leading to a 3.59-fold increase in protein production.

5 The vaccine may comprise the vector itself but it is suitably formulated as a pharmaceutical composition in combination with a pharmaceutically acceptable carrier or excipient. Such compositions form a further aspect of the invention. The compositions may be in a form suitable for oral or parenteral application.

10 Suitable carriers are well known in the art and include solid and liquid diluents, for example, water, saline or aqueous ethanol. The liquid carrier is suitably sterile and pyrogen free.

15 The compositions may be in the form of liquids suitable for infusion or injection, or syrups, suspensions or solutions, as well as solid forms such as capsules, tablets, or reconstitutable powders.

20 Constructs for use in the vaccines of the invention may be prepared by various means as will be understood in the art, ranging from modification of available constructs such as the wild-type virus using recombinant DNA technology or by synthetic means. Recombinant DNA techniques include site directed mutagenesis, optionally involving PCR amplification as illustrated hereinafter.

30 As illustrated hereinafter, recombinant vaccinia virus was constructed which expressed the structural genes of VEE as produced by a modified form of TC-83. The ability of the recombinant virus to elicit protective immune responses against virulent VEE disease was investigated.

35 In yet another embodiment, the vaccine further comprises a cytokine or an active fragment or variant thereof. The cytokine may itself be incorporated into the vaccine formulation, or more suitably, the vector may include a coding sequence which means that the cytokine is co-expressed by the vector. Examples of suitable cytokines include interleukin 2 (IL-2) and interleukin 40 6 (IL-6).

A particularly suitable cytokine is interleukin 2 (IL-2), which may be expressed from for example a vaccinia virus recombinant. IL-2 is known to be responsible for the clonal expansion of 5 antigen-activated T cells (Smith, (1984) *Reviews in Immunology* 2, 319-333).

Alternatively, antibody levels can be enhanced using other cytokines. For example, expression of IL-6 by vaccinia vectors 10 has been shown to induce a high level of IgG₁ (Ruby et al, 1992 *Vaccine Research* 1, (4), 347-356), and IL-5 and IL-6 induced mucosal IgA responses to co-expressed influenza HA (Ramsay et al, (1994) *Reproduction, Fertility and Development* 6, 389-392).

15 The vaccine of the present invention may be used to treat humans or animals. In particular it may be given to horses, as a veterinary vaccine, to prevent infection, or as a prophylactic or therapeutic vaccine for humans.

20 The vaccine of the invention may be incorporated into a multivalent vaccine in order to increase the benefit-to-risk ratio of vaccination.

25 The dosage of the vaccines of the invention will depend upon the nature of the mammal being immunised as well as the precise nature and form of the vaccine. This will be determined by the clinician responsible. However in general, when using a virus vector such as a vaccinia virus vectors, dosages of the vector 30 may be in the range of from 10⁴-10¹²pfu (pfu = particle forming units).

The vaccines of the invention will produce an immune response in test animals including the production of antibodies. These 35 antibodies may be useful in passive vaccination programmes or in diagnosis of VEE virus disease. For diagnostic purposes, the antibodies may form part of a kit as is conventional in the art.

The invention will now be illustrated by way of Example with reference to the accompanying drawings in which

40

Figure 1 shows the construction of chimeric plasmids used for

generation of recombinant vaccinia viruses;

Figure 2 shows the results of a immunofluorescence assay using polyclonal antiserum to TC-80;

5

Figure 3 is a graph showing the results of an experiment to quantify by ELISA the amount of VEE protein expressed by strains; and

10 Figure 4 is a graph showing the results of an experiment to find the level of anti-VEE IgG in animals vaccinated with various strains of the invention.

15 In the Examples, relative protein levels were calculated from ELISA data using regression analysis performed by Minitab statistical analysis software (Minitab Inc., State College, PA, USA). Serum antibody levels were compared by the two sample t test. Contingency tables were analysed by Fisher's exact test. P values of <0.05 were taken to be significant.

20

Example 1

Alteration of the E2 protein sequence

pTC-5A, a plasmid clone of cDNA encoding the structural genes of Venezuelan Equine Encephalitis virus, strain TC-83 was obtained from Dr. R. Kinney (Kinney et al, 1988, Journal of General Virology 69, 3005-3103). An Eco RI fragment containing the VEE cDNA was removed from pTC-5A and inserted into p1113 (Carroll, 1993, Ph.D. thesis, Faculty of Medicine, University of Manchester; Fig 1a) which is a shuttle vector used for insertion of genes into the thymidine kinase locus of vaccinia with dominant selection of recombinant viruses based on resistance to mycophenolic acid (Falkner & Moss, 1988, Journal of Virology 62, 1849-1854). The resulting plasmid, pAB100, was mixed with Lipofectin™ (Life Technologies) and used to transfect CV-1 cells infected with vaccinia virus, strain WR. Recombinant viruses were designated WR100 and were subjected to three rounds of plaque-purification before preparation of stocks as described earlier (Mackett et al, 1985 DNA cloning (Volume II): a practical approach).

40

The sequence of VEE E2, strain TC-83, situated in pTC-5A, was

altered by one nucleotide substitution from T to G at position 1053 as compared to wild-type VEE TRD (Johnson et al. J. Gen. Virol. 1986, 67, 1951-1960). This resulted in an amino acid change from asparagine to lysine in the E2 protein when 5 expressed from the vaccinia virus.

In order to perform this particular amino acid change, the following manipulations were carried out.

10 A cleavage site for restriction enzyme *Nsi* I occurs close to the site of the required nucleotide substitution. A second *Nsi* I site is situated about 500bp upstream. Oligonucleotide primers were used to amplify the DNA sequence between the *Nsi* I sites using the Polymerase Chain Reaction (PCR). The downstream 15 primer contained a nucleotide mismatch corresponding to the TRD sequence at this point.

The primer sequences are listed below. The *Nsi* I cleavage sites and the position of the substituted nucleotide are underlined.

20 Primer 1 designated "Nsi 1"

5' GCC GAT GCA TGT GGA AGG C 3'

25 Primer 2 designated "Nsi 2"

5' ATC TGA TGC ATC TGG CCA TGT AAG GGC GCG TTA GCT TAT
ACT CCT TAA ACA GC 3'

30 The PCR product was digested with *Nsi* I and used to replace the corresponding *Nsi* I fragment in pTC-5A, generating plasmid pAB101. The nucleotide sequence of the relevant region in pAB101 was obtained to verify the sequence alteration.

35 pAB101 was then digested with *Eco* R1 to remove the VEE 26S RNA coding sequence which was transferred to the vaccinia shuttle vector plasmid p1113. P1113 contains the selectable marker *gpt* which allows selection of recombinant vaccinia viruses. The plasmid constructed by the addition of the VEE sequence to p1113 40 was designated pAB102.

Example 2**Substitution of 7.5K promoter for a synthetic promoter in pAB102**

A synthetic 7.5K vaccinia promoter was designed, based upon work by Davison and Moss (supra.). Complementary oligonucleotides 5 were designed with 5' *Bam* HI and 3' *Eco* RI ends. The oligonucleotides were annealed and ligated into the plasmid pT7Blue (available from AMS Biotechnology (UK) Ltd). The plasmid clone was digested with *Bam* HI and *Eco* RI and the DNA fragment containing the synthetic promoter was isolated and cloned into 10 the plasmid pAB102 which had been cut with the same enzymes. This resulted in the generation of plasmid pAB103 (Figure 1) which contains the synthetic promoter upstream of the VEE 26S RNA coding sequence. Vaccinia WR strain was transformed with PAB103 to produce the recombinant vaccinia virus WR103.

15

The sequence of the oligonucleotides used is given below. Substitutions in the 7.5K promoter sequence are given in bold type. Insertions are underlined. Oligonucleotide "tails" containing restriction enzyme cleavage sites are italicised.

20

Oligo 1 designated "7.5KF2"

5' **ACG CGG ATC CAA AAA TTG AAA AAC TAG CTT AAA AAT TGA**
AAA ACT ATT CTA ATT TAT TGC ACG AAT TCC G 3'

25

Oligo 2 designated "7.5KR2"

This is the reverse complement of 7.5KF2.

30

The amount of VEE proteins produced by the recombinant virus WR103 was measured using enzyme linked immunoabsorbant assay (ELISA).

Example 3**Analysis of protein expression**

35

VEE viral proteins were visualised by indirect immunofluorescence of infected CV-1 cells. CV-1 monolayers (25cm²) were infected with virus at a multiplicity of 2 p.f.u. per cell. At 24 hours post infection, cells were scraped into the growth media and washed once with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin. Cells were 40 spotted onto slides, air-dried and fixed in acetone. Binding

of mouse polyclonal antiserum raised against VEE strain TC-80 (provided by Dr. A.D.T. Barrett, University of Texas) was detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Amersham International plc).

5

Examination of cells infected with WR100 or WR103 showed that WR103-infected cells fluoresced more brightly than the WR100-infected cells (Figure 2).

10 Quantification of VEE viral protein expression was carried out using an enzyme-linked immunosorbent assay (ELISA). CV-1 monolayers (150 cm^2) were infected with virus at a multiplicity of 10 p.f.u. per cell and harvested at 24 hours post infection by scraping into the growth media. Cells were washed once in 15 PBS and resuspended in T9 buffer (10 mM Tris.HCl; 1 mM EDTA; pH 9.0). Samples were frozen, thawed and sonicated for 1 minute in a sonicating bath. Cells debris was pelleted for 5 minutes at 1800 g and the supernatant was centrifuged for 30 minutes at 10,000 x g. The supernatant was removed and stored 20 at -70°C. The cell lysate preparation was diluted 1/30 in bicarbonate buffer (Sigma), 100 l volumes were added to wells of a microtitre plate and the antigen was allowed to bind at 37°C for 1 hour. Lysates were replaced with 200 l/well of saline containing 10% formaldehyde. Plates were incubated at 25 room temperature for 20 minutes, then washed 6 times with PBS containing 0.1% Tween (PBST). Mouse polyclonal anti-TC80 was serially diluted in blocking solution (0.5% dried milk/PBST), added to wells, and the plates were incubated for 1 hour at 37°C. Plates were washed 3 times in PBST before addition of 30 horseradish peroxidase-conjugated mouse specific antibody (diluted 1:1000 in blocking solution) and incubated for 1 hour at 37°C. Plates were washed 3 times before addition of ABTS in citrate buffer and incubation at room temperature for 1 hour. Colour development was measured at A_{414} .

35 This quantification process revealed that WR103-infected cells contained 3.59-fold more VEE protein than WR100-infected cells (Figure 3).

40 Quantification of vaccinia protein in these samples had demonstrated equivalent amounts in each (data not shown), so

it must be assumed that the difference in VEE protein content is due to different expression levels of the encoded VEE cDNA.

5 **Example 4**

Protective effect of Vaccinia recombinants

Groups (10) of female 6-8 week old Balb/c mice were inoculated with PBS or with 10^8 p.f.u. of vaccinia viruses by intra-muscular injection, or with 10^5 p.f.u. of TC-83 by sub-cutaneous injection. Serum was taken for measurement of immunoglobulins to VEE proteins.

The vaccinated mice were challenged with two different doses of virulent VEE strain TRD at 35 days after immunisation. The 15 survival rates after 14 days are presented in Table 2.

Table 2

Strain	10pfu TRD	100 pfu TRD
WR	0/10	0/10
WR100	1/10	2/10
WR103	6/10	6/10
No treatment	0/10	0/10

20 WR100: Vaccinia/VEE recombinant

WR103: Vaccinia/VEE recombinant produced in Example 2 above.

These results show that genetic manipulation of the recombinant virus has improved the protection afforded by the construct. A 25 significant improvement in protection of mice following sub-cutaneous challenge with TrD was seen when WR103 was used for vaccination, compared with WR100 ($P<0.05$, Table 2). WR100 protected up to 20% of mice whereas WR103 protected 60% of mice. There was not a significant difference between numbers 30 of mice protected when challenge doses of 10 p.f.u. or 100 p.f.u. of TrD were used. The challenge dose had previously been titrated to show that 1 p.f.u. of TrD approximates to 2-3 LD₅₀ doses (data not shown).

Example 5**Immunoassays**

VEE virus-specific immunoglobulin in serum was measured by enzyme-linked immunoassay as follows. Wells of a microtitre plate were coated with purified TC-83 at 37°C for 1 hour. Serum was diluted serially in blocking solution and allowed to bind to antigen-coated wells overnight at 4°C. Plates were washed 3 times and incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulin at 37°C for 1 hour. Plates were washed and incubated with TMB substrate for 20 minutes before measurement of colour development at A_{450} .

All vaccinia-inoculated mice responded to the vaccination by the detection of immunoglobulin to vaccinia virus in serum (data not shown). Immunoassay to measure TC-83 antibody failed to detect anti-VEE IgG in WR100 samples. WR103 samples contained a detectable level of anti-VEE antibody although this was substantially lower than the amount found in serum from mice vaccinated with TC-83 (Figure 4).

Neutralising antibody was measured by a plaque reduction test. Serum (10 μ l) was incubated with TC-83 (50 μ l) and maintenance medium (140 μ l) for 1 hour at room temperature. Maintenance medium (800 μ l) was added and the suspension was used to infect confluent monolayers of BHK-21 cells grown in 6-well plates. Plates were incubated at 37°C for 3 days. A 50% reduction in the number of plaques per well, compared to control wells, was indicative of the presence of neutralising antibody.

Neutralising antibody to TC-83 was found in serum from mice vaccinated with TC-83 but was not detected in serum from mice vaccinated with WR100 or WR103 (data not shown). Although neutralising antibody is usually found in mice which are protected against VEE challenge, protection has previously been reported in the absence of detectable neutralising antibody (Kinney et al, 1988a, Journal of Virology 62, 4697-4702).

Claims

1. A vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vector which includes a sequence which encodes an attenuated form of said virus which is capable of producing a protective immune response, wherein the said sequence is such that the amino acid at position 7 in the E2 protein of VEE is lysine.
10
2. A vaccine according to claim 1 wherein the attenuated form of said virus comprises a derivative of the TC-83 construct.
15
3. A vaccine according to claim 2 wherein the vector comprises a virus vector.
15
4. A vaccine according to claim 3 wherein the virus is selected from an attenuated virus
20
5. A vaccine according to claim 3 or claim 4 wherein the virus is selected from vaccinia, adenovirus, HSV, BCG or BCC.
25
6. A vaccine according to claim 5 which comprises an attenuated vaccinia virus.
30
7. A vaccine according to claim 6 wherein expression of the said attenuated VEE virus is under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus protein production as compared to the wild-type 7.5K promoter.
35
8. A vaccine according to claim 7 wherein the said 7.5K promoter comprises a sequence selected from
TAAAAAATTGAAAATACATTCTAATTATTGCAC (SEQ ID No 2)
or
TAAAAAATTGAAAATATATTCTAATTATTGCAC (SEQ ID No 3).
35
9. A vaccine according to any one of the preceding claims which comprises a vector which includes a nucleotide sequence which encodes a further immunogenic peptide, and is able to express said sequence when administered to a mammal.
40

10. A vaccine according to any one of the preceding claims which further comprises a cytokine or an active fragment or variant thereof, or a vector which comprises a nucleotide sequence which encodes a cytokine or an active fragment or
5 variant thereof.

11. A vaccine according to claim 10 which comprises a vector which comprises a nucleotide sequence which encodes a cytokine or an active fragment or variant thereof.

10 12. A vaccine according to claim 10 or claim 11 wherein the cytokine is an interleukin.

15 13. A vaccine according to claim 10 wherein the interleukin is selected from human IL-2 or human IL-6.

14. A vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vaccinia virus vector which encodes an attenuated
20 form of the VEE virus or a variant or fragment thereof which is capable of producing a protective immune response against VEE virus, expression of the said attenuated VEE virus being under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus
25 protein production as compared to the wild-type 7.5K promoter


30 15. A pharmaceutical composition comprising a vaccine as defined in any one of the preceding claims and a pharmaceutically acceptable carrier or excipient.

16. A method for producing a protective immune response against VEE virus in a mammal, which method comprises administering to said mammal, a vaccine according to any one of claims 1 to 14.

35 17. A method according to claim 16 wherein the mammal is either a human or a horse.


40 18. A multivalent vaccine comprising a vaccine according to any one of claims 1 to 14 and a further vaccine.

Fig. 1(a).



SUBSTITUTE SHEET (RULE 26)

Fig.2.



SUBSTITUTE SHEET (RULE 26)

Fig.3.





Fig. 4.



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/01387

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/63 A61K39/12 A61K39/295

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KINNEY R M ET AL: "Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins." JOURNAL OF GENERAL VIROLOGY, (1988 DEC) 69 (PT 12) 3005-13. , XP002118353 cited in the application page 3005 -page 3006 page 3007; figure 1</p> <p>---</p> <p>DAVISON, ANDREW J. ET AL: "Structure of vaccinia virus early promoters" J. MOL. BIOL. (1989), 210(4), 749-69 , XP002118354 page 749 page 767, left-hand column -page 769, right-hand column</p> <p>---</p> <p>---</p> <p style="text-align: right;">-/-</p>	14-18
Y		14-18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

11 October 1999

22.10.99

Name and mailing address of the ISA	Authorized officer
-------------------------------------	--------------------

European Patent Office, P.B. 5818 Patentbaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Mennessier, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01387

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KINNEY R M ET AL: "The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83." VIROLOGY, (1989 MAY) 170 (1) 19-30. , XP002117670 the whole document ---	1-18
A	HUNT A R ET AL: "Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses." VACCINE, (1995 FEB) 13 (3) 281-8. , XP004057668 cited in the application the whole document ---	1-18
A	AGAPOV E V ET AL: "Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection." ARCHIVES OF VIROLOGY, (1994) 139 (1-2) 173-81. , XP002117671 the whole document ---	1-18
A	US 5 185 440 A (JOHNSTON ROBERT E ET AL) 9 February 1993 (1993-02-09) the whole document ---	1-18
P,X	BENNETT A M ET AL: "Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus." VIRAL IMMUNOLOGY, (1998) 11 (3) 109-17. , XP002117672 the whole document -----	1-18

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/GB 99/01387**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 16-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the vaccine.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01387

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5185440	A 09-02-1993	NONE	

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)